A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer

NCT06577194 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer
Advanced Solid Tumor

Interventions

DRUG: Sintilimab + IL-2 Combined with CAPOX
RADIATION: Short-course radiotherapy

Sponsor

The First Affiliated Hospital with Nanjing Medical University